Immupharma PLC (LON:IMM) remains upbeat there are still commercial avenues open for its lupus treatment Lupuzor and talks are ongoing with regulators in the US about a new phase III trial.
Tim McCarthy, Immuphrama’s chairman, said: "With further analysis gained from our Phase III results, together with our extension study successfully meeting its endpoint confirming its safety profile, we are focused on progressing Lupuzor into a further Phase III trial."
The biotech had intended to run a managed access program for patients who request their doctor to prescribe Lupuzor, but this has now been postponed to focus on a new trial.
Immupharma has two other platforms, Ureka Sarl (Peptide) and Elro Pharma (Nucant), where the options under consideration are to license, divest or 'spin-off' the technologies.
Losses in the six months to June were £3.9mln (£4.1mln), with cash at the period-end of £2.3mln.